DRREDDY vs KOPRAN: Stock Comparison

Dr Reddys Laboratories Ltd vs Kopran Limited

Live data: 22 July 2026, 3:02 PM IST • Source: NSE and company filings

Dr Reddys Laboratories Ltd is the larger company by market capitalisation. Dr Reddys Laboratories Ltd shows a lower P/E, a higher ROE and lower leverage, while Kopran Limited shows a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Dr Reddys Laboratories Ltd and Kopran Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, DRREDDY is more favourable on 7 of 13 scored metrics and KOPRAN on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DRREDDY is the larger company
₹98,815 Cr vs ₹942 Cr
P/E Ratio
DRREDDY has a lower P/E
24x vs 38.28x
P/B Ratio
KOPRAN has a lower P/B
1.86x vs 2.66x
EPS
DRREDDY has higher earnings per share
₹51.37 vs ₹3.41
Dividend Yield
KOPRAN has a higher dividend yield
1.59% vs 0.65%
Revenue Growth (TTM YoY)
KOPRAN has faster revenue growth
-3.66% vs -11.6%
EPS Growth (TTM YoY)
KOPRAN has faster EPS growth
-71.88% vs -86.2%
Qtr Sales Growth
KOPRAN has stronger quarterly sales growth
-3.03% vs -11.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDRREDDYKOPRAN
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricDRREDDYKOPRAN
Live Price₹1,183.7₹206.27
Day Change-1.85%6.56%
Volume21.17 L38.55 L
52-Week High₹1,414.9₹219
52-Week Low₹1,148.4₹107
Distance from 52W High-16.34%-5.81%

Valuation

MetricDRREDDYKOPRAN
Market Cap₹98,815 Cr₹942 Cr
P/E Ratio24x38.28x
P/B Ratio2.66x1.86x
EPS₹51.37₹3.41
Book Value₹452.82₹107.35
Dividend Yield0.65%1.59%

Growth

MetricDRREDDYKOPRAN
Revenue Growth (TTM YoY)-11.6%-3.66%
EPS Growth (TTM YoY)-86.2%-71.88%
Qtr Sales Growth-11.5%-3.03%
Qtr Profit Growth-86.1%-32.9%

Profitability & Leverage

MetricDRREDDYKOPRAN
ROE11.2%4.85%
ROCE13%9.75%
Net Margin12.76%3.78%
Operating Margin19.2%6.58%
Debt to Equity0.2x0.29x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricDRREDDYKOPRAN
Promoter Holding26.63% 0.01 pp44.42%
FII Holding33.08% 0.12 pp0.51% 0.06 pp
DII Holding30.72% 0.28 pp0%
Public Holding9.33% 0.14 pp55.06% 0.06 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Dr Reddys Laboratories Ltd and Kopran Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.